rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BNTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioNTech: Priority Review Voucher Purchase Hints At Much Needed Approval Shot
      Nov 17Seeking AlphaBNTX
      BioNTech (BNTX) Stock Looks Fully Valued As Sales Face Pressure
      Nov 13Yahoo FinanceBNTX
      Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
      Nov 13Yahoo FinanceBNTX
      BioNTech (BNTX) Dropped, So What Is Driving Attention Now?

      BioNTech (NasdaqGS:BNTX) is back in focus after Arbutus Biopharma and Genevant expanded their patent enforcement campaign by filing new lawsuits in Japan and updating an existing Canadian case tied to mRNA lipid nanoparticle technology. Investors have watched BioNTech give back ground over 2026, with the share price down 12.05% year to date and the 1 year total shareholder return declining 18.14%. This suggests momentum has been fading even as fresh earnings, updated guidance and buybacks...

      Nov 13Yahoo FinanceBNTX
      The Next Chapter of mRNA

      Moderna, led by CEO Stéphane Bancel, is forging the future of mRNA with its new personalized cancer vaccine.

      Nov 12TimeBNTXMRNA
      Buy BioNTech Stock. It May Be the Next Moderna.

      BioNTech has multiple catalysts that could generate a rally of 35% for the stock.

      Nov 12Barron'sBNTX
      BioNTech to buy Scholar Rock PRV for $205M (BNTX:NASDAQ)
      Nov 10Seeking AlphaBNTXSRRK
      BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027 | The Motley Fool

      Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

      Nov 9The Motley FoolBNTX
      Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
      Nov 6Yahoo FinanceBNTXMRNAPFE
      Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Sanofi (OtherSNYNF)

      Tipranks Press Release.

      Nov 5The Globe and MailBNTXSNY
      BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
      Nov 4Seeking AlphaBNTXBMY
      Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment
      Nov 4Yahoo FinanceBNTX
      BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo
      Nov 4Yahoo FinanceBNTX
      BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...
      Nov 4Yahoo FinanceBNTX
      Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
      Nov 3Yahoo FinanceBNTXMRNAMRKPFE
      BioNTech Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceBNTX
      BioNTech Q3 2026 slides: oncology pipeline advances as revenue guidance rises
      Nov 3Investing.comBNTX
      Earnings call transcript: BioNTech beats Q3 2026 estimates as stock rises premarket
      Nov 3Investing.comBNTX
      BioNTech Q3 2026 Earnings Call Transcript
      Nov 3BenzingaBNTX
      BioNTech Lifts Outlook Boosted by Cancer Drug Milestone Payments
      Nov 3BloombergBNTXBMY
      BioNTech earnings beat by €0.98, revenue topped estimates
      Nov 3Investing.comBNTX
      BioNTech shares rise 3% on beating Q3 estimates, raised 2026 revenue guidance
      Nov 3Investing.comBNTX
      BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

      Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecanAdvanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median ove

      Nov 3Yahoo FinanceBNTX
      BioNTech earnings up next: Can revenue rebound offset cancer setback?
      Nov 2Investing.comBNTX
      BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning
      Oct 28Yahoo FinanceBNTX
      Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
      Oct 28Yahoo FinanceBNTXMRNANVAX
      Why Is BioNTech Stock Falling Today? - BioNTech (NASDAQ:BNTX)
      Oct 26BenzingaBNTX
      Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
      Oct 26Yahoo FinanceBNTXMRNAPFE
      BioNTech, DualityBiologics' Late-Stage Trial of Metastatic Breast Cancer Therapy Meets Primary Endpoint; Severe, Fatal Events Reported
      Oct 26Yahoo FinanceBNTX
      BioNTech, DualityBio cancer drug trial meets primary endpoint
      Oct 26Investing.comBNTX
      BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
      Oct 25Yahoo FinanceBNTX
      BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
      Oct 25Yahoo FinanceBNTX
      Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
      Oct 23Yahoo FinanceBNTXMRNAMRKPFE
      BioNTech, Gilead to test drug combination in advanced breast cancer trial
      Oct 22ReutersBNTXGILD
      BioNTech, Gilead collaborate on triple-negative breast cancer trial
      Oct 22Investing.comBNTXGILD
      BioNTech (BNTX) Stock May Be Fully Valued Despite Fresh Oncology Data Preview
      Oct 22Yahoo FinanceBNTX
      Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
      Oct 17Yahoo FinanceBNTXMRNA
      Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)
      Oct 17Yahoo FinanceBNTX
      Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
      Oct 15Yahoo FinanceBNTXMRNAPFE
      BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
      Oct 14MorningstarBNTX
      BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?
      Oct 14Yahoo FinanceBNTX
      BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles
      Oct 13Yahoo FinanceBNTX
      What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?
      Oct 13Yahoo FinanceBNTX
      BioNTech mRNA cancer immunotherapy misses first objective in key study
      Oct 13Yahoo FinanceBNTX
      Why Is BioNTech Stock Falling Tuesday? - BioNTech (NASDAQ:BNTX)

      BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.

      Oct 13BenzingaBNTX
      BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’
      Oct 13Yahoo FinanceBNTX
      BioNTech's mRNA cancer therapy misses first goal in head and neck trial
      Oct 13ReutersBNTX
      BioNTech cancer drug fails to meet trial goal
      Oct 13Investing.comBNTX
      BMO Capital Reaffirms Their Hold Rating on BioNTech SE (BNTX)

      Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailBNTX
      BioNTech Shares Fall 5% as BNT113 Cancer Trial Misses Progression-Free Survival Endpoint
      Oct 13Yahoo FinanceBNTX

      This is the newest page. Registered accounts read further back.